Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: Development of novel bladder preservation approach, Osaka Medical College regimen

Haruhito Azuma, Teruo Inamoto, Kiyoshi Takahara, Naokazu Ibuki, Hayahito Nomi, Kazuhiro Yamamoto, Yoshihumi Narumi, Takanobu Ubai

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Cisplatin-based chemotherapy has been widely used in a neoadjuvant as well as adjuvant setting. Furthermore, trimodal approaches including complete transurethral resection of the bladder tumor followed by combined chemotherapy and radiation have generally been performed as bladder preservation therapy. However, none of the protocols have achieved a 5-year survival rate of more than 70%. Additionally, the toxicity of chemotherapy and/or a decreased quality of life due to urinary diversion cannot be ignored, as most patients with bladder cancer are elderly. We therefore newly developed the novel trimodal approach of "combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation, which delivers an extremely high concentration of anticancer agent to the site of a tumor without systemic adverse effects ("Osaka Medical College regimen" referred to as the OMC regimen). We initially applied the OMC regimen as neoadjuvant chemotherapy for locally advanced bladder cancer. However, since more than 85% of patients with histologically-proven urothelial cancer achieved complete response with no evidence of recurrence after a mean follow-up of 170 (range 21-814) weeks, we have been applying the OMC-regimen as a new approach for bladder sparing therapy. We summarize the advantage and/or disadvantage of chemotherapy in neoadjuvant as well as adjuvant settings, and show the details of our newly developed bladder sparing approach OMC regimen in this review.

Original languageEnglish
Pages (from-to)26-38
Number of pages13
JournalInternational Journal of Urology
Volume19
Issue number1
DOIs
Publication statusPublished - 01-01-2012
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Urinary Bladder
Carcinoma
Drug Therapy
Urinary Bladder Neoplasms
Antineoplastic Agents
Radiation
Urinary Diversion
Cisplatin
Renal Dialysis
Neoplasms
Therapeutics
Survival Rate
Quality of Life
Recurrence

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Azuma, Haruhito ; Inamoto, Teruo ; Takahara, Kiyoshi ; Ibuki, Naokazu ; Nomi, Hayahito ; Yamamoto, Kazuhiro ; Narumi, Yoshihumi ; Ubai, Takanobu. / Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma : Development of novel bladder preservation approach, Osaka Medical College regimen. In: International Journal of Urology. 2012 ; Vol. 19, No. 1. pp. 26-38.
@article{b1303b24aa23458a87941b56424753ab,
title = "Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: Development of novel bladder preservation approach, Osaka Medical College regimen",
abstract = "Cisplatin-based chemotherapy has been widely used in a neoadjuvant as well as adjuvant setting. Furthermore, trimodal approaches including complete transurethral resection of the bladder tumor followed by combined chemotherapy and radiation have generally been performed as bladder preservation therapy. However, none of the protocols have achieved a 5-year survival rate of more than 70{\%}. Additionally, the toxicity of chemotherapy and/or a decreased quality of life due to urinary diversion cannot be ignored, as most patients with bladder cancer are elderly. We therefore newly developed the novel trimodal approach of {"}combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation, which delivers an extremely high concentration of anticancer agent to the site of a tumor without systemic adverse effects ({"}Osaka Medical College regimen{"} referred to as the OMC regimen). We initially applied the OMC regimen as neoadjuvant chemotherapy for locally advanced bladder cancer. However, since more than 85{\%} of patients with histologically-proven urothelial cancer achieved complete response with no evidence of recurrence after a mean follow-up of 170 (range 21-814) weeks, we have been applying the OMC-regimen as a new approach for bladder sparing therapy. We summarize the advantage and/or disadvantage of chemotherapy in neoadjuvant as well as adjuvant settings, and show the details of our newly developed bladder sparing approach OMC regimen in this review.",
author = "Haruhito Azuma and Teruo Inamoto and Kiyoshi Takahara and Naokazu Ibuki and Hayahito Nomi and Kazuhiro Yamamoto and Yoshihumi Narumi and Takanobu Ubai",
year = "2012",
month = "1",
day = "1",
doi = "10.1111/j.1442-2042.2011.02856.x",
language = "English",
volume = "19",
pages = "26--38",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "1",

}

Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma : Development of novel bladder preservation approach, Osaka Medical College regimen. / Azuma, Haruhito; Inamoto, Teruo; Takahara, Kiyoshi; Ibuki, Naokazu; Nomi, Hayahito; Yamamoto, Kazuhiro; Narumi, Yoshihumi; Ubai, Takanobu.

In: International Journal of Urology, Vol. 19, No. 1, 01.01.2012, p. 26-38.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma

T2 - Development of novel bladder preservation approach, Osaka Medical College regimen

AU - Azuma, Haruhito

AU - Inamoto, Teruo

AU - Takahara, Kiyoshi

AU - Ibuki, Naokazu

AU - Nomi, Hayahito

AU - Yamamoto, Kazuhiro

AU - Narumi, Yoshihumi

AU - Ubai, Takanobu

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Cisplatin-based chemotherapy has been widely used in a neoadjuvant as well as adjuvant setting. Furthermore, trimodal approaches including complete transurethral resection of the bladder tumor followed by combined chemotherapy and radiation have generally been performed as bladder preservation therapy. However, none of the protocols have achieved a 5-year survival rate of more than 70%. Additionally, the toxicity of chemotherapy and/or a decreased quality of life due to urinary diversion cannot be ignored, as most patients with bladder cancer are elderly. We therefore newly developed the novel trimodal approach of "combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation, which delivers an extremely high concentration of anticancer agent to the site of a tumor without systemic adverse effects ("Osaka Medical College regimen" referred to as the OMC regimen). We initially applied the OMC regimen as neoadjuvant chemotherapy for locally advanced bladder cancer. However, since more than 85% of patients with histologically-proven urothelial cancer achieved complete response with no evidence of recurrence after a mean follow-up of 170 (range 21-814) weeks, we have been applying the OMC-regimen as a new approach for bladder sparing therapy. We summarize the advantage and/or disadvantage of chemotherapy in neoadjuvant as well as adjuvant settings, and show the details of our newly developed bladder sparing approach OMC regimen in this review.

AB - Cisplatin-based chemotherapy has been widely used in a neoadjuvant as well as adjuvant setting. Furthermore, trimodal approaches including complete transurethral resection of the bladder tumor followed by combined chemotherapy and radiation have generally been performed as bladder preservation therapy. However, none of the protocols have achieved a 5-year survival rate of more than 70%. Additionally, the toxicity of chemotherapy and/or a decreased quality of life due to urinary diversion cannot be ignored, as most patients with bladder cancer are elderly. We therefore newly developed the novel trimodal approach of "combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation, which delivers an extremely high concentration of anticancer agent to the site of a tumor without systemic adverse effects ("Osaka Medical College regimen" referred to as the OMC regimen). We initially applied the OMC regimen as neoadjuvant chemotherapy for locally advanced bladder cancer. However, since more than 85% of patients with histologically-proven urothelial cancer achieved complete response with no evidence of recurrence after a mean follow-up of 170 (range 21-814) weeks, we have been applying the OMC-regimen as a new approach for bladder sparing therapy. We summarize the advantage and/or disadvantage of chemotherapy in neoadjuvant as well as adjuvant settings, and show the details of our newly developed bladder sparing approach OMC regimen in this review.

UR - http://www.scopus.com/inward/record.url?scp=84855202486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855202486&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2011.02856.x

DO - 10.1111/j.1442-2042.2011.02856.x

M3 - Review article

C2 - 22077821

AN - SCOPUS:84855202486

VL - 19

SP - 26

EP - 38

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 1

ER -